Summary

Efepoetin alfa is a synthetic erythropoiesis-stimulating agent (ESA) that mimics erythropoietin (EPO) through a peptide scaffold. Unlike recombinant EPO proteins, efepoetin alfa uses a designed peptide that reproduces EPO's receptor-binding activity. It has completed Phase 3 trials for the treatment of anaemia in chronic kidney disease (CKD), demonstrating non-inferiority to methoxy polyethylene glycol-epoetin beta. The compound exemplifies structure-based peptide design applied to a clinically important target. For research and educational purposes only.

Mechanism

Efepoetin alfa is a peptide mimetic of erythropoietin (EPO). It binds and activates the erythropoietin receptor (EPOR), triggering JAK2/STAT5 signalling that stimulates erythroid progenitor cell proliferation, differentiation, and red blood cell production. The peptide scaffold reproduces the receptor-binding epitope of EPO without requiring the full 165-amino-acid glycoprotein structure.

Evidence base

Strong evidence — Phase 3 randomised, active-controlled trial (NCT05109593; PMID 40369895) demonstrated non-inferiority to methoxy polyethylene glycol-epoetin beta in maintaining haemoglobin levels in Stage 3-4 CKD patients with anaemia. Safety profile consistent with the ESA class. Evidence for non-CKD indications remains investigational.

Key trial: NCT05109593; published 2025 (PMID: 40369895)

Protocols

Phase 3 dose (SC): Subcutaneous injection, dose by body weight and baseline haemoglobin, monthly dosing interval.

Titration: Haemoglobin monitored every 2-4 weeks; dose adjusted to maintain 10-12 g/dL.

Iron: Maintain TSAT ≥20% and ferritin ≥100 ng/mL.

Research use only — not medical advice.

UK Status: POM (Prescription-Only Medicine)

Efepoetin alfa is classified as a prescription-only medicine. It is not currently MHRA-licensed (regulatory submissions in progress). It is not a controlled substance under the Misuse of Drugs Act 1971. Research institutions may source non-clinical material for in vitro or animal research under appropriate licensing.

Vendor notes

Efepoetin alfa is an investigational pharmaceutical, not typically available from research peptide vendors. Source through clinical trial supply chains or certified research chemical suppliers with COAs.

References

  1. Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial. PubMed. 2025. PMID: 40369895.
  2. ClinicalTrials.gov. NCT05109593. A Study to Evaluate the Efficacy and Safety of Efepoetin Alfa in Participants With CKD and Anaemia.
  3. Jelkmann W. Erythropoietin: Structure, Control of Production, and Function. Physiol Rev. 1992;72(2):449-489.
  4. Elliott S, Pham E, Macdougall IC. Erythropoietins: A Common Mechanism of Action. Exp Hematol. 2008;36(1):24-34.